SCHEMBL5210241

SCHEMBL5210241

CCOC(=O)C(C=O)Oc1ccc(Cl)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 8/20 0.48
CYP1A2 P05177 3/20 0.48
TSHR P16473 2/20 0.48
ABCB11 O95342 1/20 0.48
CYP3A4 P08684 1/20 0.48
HTR2A P28223 1/20 0.48
PMP22 Q01453 1/20 0.48
EPHX2 P34913 2/20 0.46
PPARG P37231 7/20 0.43
CYP2C9 P11712 2/20 0.41
CYP2C19 P33261 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
OPRK1 P41145 1/20 0.41
KMT2A Q03164 1/20 0.41
ALDH1A1 P00352 3/20 0.40
TDP1 Q9NUW8 2/20 0.40
MAPT P10636 2/20 0.40
GAA P10253 1/20 0.40
LMNA P02545 1/20 0.40
CYP2D6 P10635 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5204140 0.84 PPARG (0.46) PPARATSHREPHX2PPARGCYP2C19
SCHEMBL11785469 0.84 LMNA (0.47) CYP1A2TSHRCYP3A4CYP2C9CYP2C19
SCHEMBL11778290 0.84 KMT2A (0.45) PPARACYP1A2PPARGCYP2C9CYP2C19
SCHEMBL27363641 0.84 TDP1 (0.49) TSHRSMN1; SMN2KMT2AALDH1A1TDP1
SCHEMBL11782411 0.84 CYP2C19 (0.43) PPARACYP1A2TSHRCYP3A4PPARG
SCHEMBL5711753 0.80 PPARA (0.53) PPARACYP1A2TSHRABCB11CYP3A4
SCHEMBL11781765 0.80 SMN1; SMN2 (0.51) PPARACYP1A2TSHRCYP3A4CYP2C9
SCHEMBL11786127 0.80 MAPT (0.54) HTR2ASMN1; SMN2KMT2AALDH1A1MAPT
SCHEMBL11785904 0.80 KMT2A (0.55) CYP1A2EPHX2CYP2C19SMN1; SMN2OPRK1
SCHEMBL5204883 0.79 EPHX2 (0.66) PPARACYP1A2TSHRABCB11CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1165523-B1 NEUROTROPHIC SUBSTITUTED PYRIMIDINES KRENITSKY PHARMACEUTICALS INC (US) 2007-11-07 EP disclosed
US-6916820-B1 Neurotrophic substituted pyrimidines KRENITSKY PHARMACEUTICALS, INC. (US) 2005-07-12 US disclosed
US-6583148-B1 Neurodegenerative or other neurological disorders; enhancing the effect of nerve growth factor; 2-Amino-5-(4-chlorophenoxy)-4-trans-4-hydroxycyclohexylamino) pyrimidine KRENITSKY PHARMACEUTICALS, INC. 2003-06-24 US disclosed
US-6440965-B1 Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system KRENITSKY PHARMACEUTICALS, INC. 2002-08-27 US disclosed
EP-1165523-A1 NEUROTROPHIC SUBSTITUTED PYRIMIDINES Krenitsky Pharmaceuticals, Inc. (US) 2002-01-02 EP disclosed
WO-2000061562-A1 NEUROTROPHIC SUBSTITUTED PYRIMIDINES KRENITSKY PHARMACEUTICALS INC. (US) 2000-10-19 WO disclosed
EP-1025091-A1 SUBSTITUTED PYRIMIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE OR NEUROLOGICAL DISORDERS OF THE CENTRAL NERVOUS SYSTEM Krenitsky Pharmaceuticals, Inc. (US) 2000-08-09 EP disclosed
WO-1999019305-A2 SUBSTITUTED PYRIMIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE OR NEUROLOGICAL DISORDERS OF THE CENTRAL NERVOUS SYSTEM KRENITSKY PHARMACEUTICALS INC. (US) 1999-04-22 WO disclosed